semaglutide light headed Why You Might Tolerate One Weight Loss Drug Better Than Another How to Manage (or Prevent)

The most consequential pending readout is TRANSCEND-T2D-2, the head-to-head trial pitting retatrutide against semaglutide in type 2 diabetes over 80 weeks

If you experience any sudden or severe symptoms at any point during treatment, seek urgent medical attention and do not wait for your next scheduled appointment

Tirzepatide (Zepbound/Mounjaro) is a dual agonist that activates two hormone receptors: GLP-1 and GIP

A microcolorimetric determination of creatine in urine by the Jaffe reaction

Convenient No needles, no water required, and easy to take anywhere

doi: 10.3389/fendo.2026.1781416 Received 05 January 2026 Revised 13 February 2026 Accepted 16 February 2026 Published 05 March 2026 Volume 17 - 2026 Edited by Lus Pedro Rato, University of vora, Portugal Reviewed by Annekathrin Martina Keiler, Technical University Dresden, Germany Weeratian Tawanwongsri, Walailak University, Thailand Updates Copyright 2026 Kowalik, Harasny, Kaliczyska, Reweda-Kwiatkowski, Starzyski, Pawlak, Waloryszak, Ptak, Modrzejewski and Lisman